grey glp-1 Weight Loss Study: Weekly GLP-1 therapy for

470 In this study, researchers randomized 529 patients with heart failure with a preserved ejection fraction and body mass index (weight in kilograms in the square of the height in meters) 30 to receive once-weekly injections of semaglutide (2.4 mg) or placebo for 52 weeks

doi: 10.1016/0014-5793(95)01006-Z 119 FalkoJMCrockettSECatalandSMazzaferriEL

Koob GF

This phenomenon is further illustrated by results from a randomized, open-label mechanistic trial in patients with T2DM, which demonstrated that lixisenatide, with a half-life of 2 4 hours, had a significantly greater effect than liraglutide in delaying in gastric emptying and curtailing postprandial glucose excursions following a standardized solid breakfast (156)